ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: ACS Board Names McGinnis Prsident; Fuller Re-Elected chairman; Lenhard Is Vice President

November 25, 1994

Hammer Gives $100,000 to Expand Rosenberg’s T-Cell Growth Factor Clinical Studies

March 1, 1985

NCI Plans Conference To Reconsider Breast Cancer Screening In women 40-49

April 19, 1996

Price Increase

July 22, 1983

Gavel Changes Hands At NCAB, Korn advises New Members On Role

February 8, 1991

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011